Market research
PRPO Precipio Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 39M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- Not available
- Beta
- 1.3
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- Not available
- Market cap
- 39M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- Not available
- Beta
- 1.3
About
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Research context
Precipio Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PRPO discussion.
5 years, 6 months ago
Precipio, Inc is currently in a long term uptrend where the price is trading 17.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Precipio, Inc's total revenue rose by 344.8% to $3M since the same quarter in the previous year.
Its net income has increased by 100.0% to $-2K since the same quarter in the previous year.
Finally, its free cash flow grew by 31.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Precipio, Inc gets an overall score of 5/5.